par Ignatiadis, Michail 
;Abdel Azim, Hatem Hamdy ;Desmedt, Christine ;Veys, Isabelle ;Larsimont, Denis ;Salgado, Roberto;Lyng, Maria B;Viale, Giuseppe;Leyland-Jones, Brian;Giobbie-Hurder, Anita;Kammler, Rosita;Dell'Orto, Patrizia;Rothé, Françoise ;Laïos, Ioanna;Ditzel, Henrik J;Regan, Meredith M;Piccart-Gebhart, Martine ;Michiels, Stefan ;Sotiriou, Christos
Référence JAMA oncology, 2, 2, page (217-224)
Publication Publié, 2016-02
;Abdel Azim, Hatem Hamdy ;Desmedt, Christine ;Veys, Isabelle ;Larsimont, Denis ;Salgado, Roberto;Lyng, Maria B;Viale, Giuseppe;Leyland-Jones, Brian;Giobbie-Hurder, Anita;Kammler, Rosita;Dell'Orto, Patrizia;Rothé, Françoise ;Laïos, Ioanna;Ditzel, Henrik J;Regan, Meredith M;Piccart-Gebhart, Martine ;Michiels, Stefan ;Sotiriou, Christos Référence JAMA oncology, 2, 2, page (217-224)
Publication Publié, 2016-02
Article révisé par les pairs
| Résumé : | The Genomic Grade Index (GGI) was previously developed, evaluated on frozen tissue, and shown to be prognostic in early breast cancer. To test the GGI in formalin-fixed, paraffin-embedded breast cancer tumors, a quantitative reverse transcriptase polymerase chain reaction assay was developed and named the Genomic Grade (GG). The GG assay has the potential to increase the clinical application of the GGI, but robust demonstration of the clinical validity of the GG assay is required. |
